Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07018297 · ClinicalTrials.gov registry record · Phase 3
Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure
A Phase 3 study, sponsored by University of Texas Southwestern Medical Center.
- Not yet
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
NCT07018297: Clinical Trial Phase 3 study, sponsored by University of Texas Southwestern Medical Center.
NCT07018297 is a Phase 3 study that has not yet begun recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 250 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07018297, a Phase 3 study, has not yet begun recruiting, sponsored by University of Texas Southwestern Medical Center.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
Study Summary
This will be a prospective, cluster-randomized, crossover, non-inferiority trial of 250 participants within 48 hours of an inpatient admission for heart failure or emergency department presentation for heart failure with plans for admission or observation/short-stay hospitalization comparing early discharge using subcutaneous furosemide to standard inpatient care. Individual practice groups will serve as "clusters" and the unit of randomization. Each participating cluster will implement either the early discharge strategy using the intervention or standard care for initial two-month blocks, followed by a crossover to the alternate strategy. The primary outcome is days alive and out of hospital at 30 days.
Primary Outcome
Days alive and out of the hospital will be ascertained via retrospective review of the electronic health record.
Interventions
- COMBINATION_PRODUCT Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2026-08 |
| Est. Completion | 2028-09-01 |
| Phase | Phase 3 |
What is known before NCT07018297 opens enrollment
NCT07018297 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 1 intervention - of which Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor is the first listed.
NCT07018297 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07018297 about?
NCT07018297 is a clinical study titled "Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure". This will be a prospective, cluster-randomized, crossover, non-inferiority trial of 250 participants within 48 hours of an inpatient admission for heart failure or emergency department presentation for heart failure with plans for admission or observation/short-stay hospitalization comparing early d...
What is the current status of trial NCT07018297?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2026-08. Estimated completion is 2028-09-01.
What interventions are being tested in trial NCT07018297?
The interventions under investigation include: Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07018297?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07018297's enrollment target sits among peer trials
250 1249th of 2000 higher than 735 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia